Showing the latest 10 filings. Sign in to filter or browse the full history. View full history
Showing 10 of 90 filings.
22 Sept 2026 1 filing
Meeting Details
Board meeting on Oct 23, 2026; time and venue not disclosed.
Key Agenda Items
To consider and approve unaudited standalone and consolidated financial results for quarter ending Sep 30, 2026.
Other Notes
Trading window closed from Sep 24, 2026 to Oct 25, 2026 inclusive.
21 Sept 2026 1 filing
Meeting Details
Date: 25 September 2026; Time: 11:00–14:00 IST.
Type and mode: group, in-person investor meeting.
Organizer: Nomura.
Location: Hyderabad.
Purpose: analyst/institutional investor meeting.
Participants: company management.
18 Sept 2026 2 filings
Agreement overview
Dr. Reddy's enters exclusive distribution and marketing deal for Qdenga in India's private market.
Key terms
No upfront payment or milestones; terms confidential.
Scope of rights
Dr. Reddy's to distribute in private market; Takeda retains public-market rights and handles manufacturing/import.
Regulatory and timing
CDSCO approved QDENGA in July 2026 for individuals aged 4-60 years; private-market launch anticipated H1 2027.
Strategic rationale
Partnership strengthens India's vaccines business; creates private-market access pathway for QDENGA.
Clarification on lenacapavir license media report
Clarifies media report on voluntary license for lenacapavir is correct per Sept 17, 2026 press release.
There is no material event or undisclosed information requiring disclosure under Regulation 30.
No sequence of negotiations to disclose.
No regulatory or legal proceedings initiated or outcomes disclosed.
Media item relates to press release; not a material event.
17 Sept 2026 1 filing
No brief for this announcement. This type of announcement aren’t summarised. View the original using the link below
16 Sept 2026 1 filing
No brief for this announcement. Newspaper publications aren’t summarised. View the original using the link below
11 Sept 2026 1 filing
USFDA assessment at DRL Mexico API facility
US FDA completed a records assessment at DRL's API facility Industrias Químicas Falcón de México in Jiutepec, Morelos.
The assessment occurred between July 17, 2026 and September 8, 2026.
USFDA issued two observations; DRL will respond within the stipulated timeline.
10 Sept 2026 2 filings
No brief for this announcement. This type of announcement aren’t summarised. View the original using the link below
Meeting Details
2026, 12:30–13:30 IST, in-person group meeting in Hyderabad organized by ICICI Securities.
2026, 14:00–15:00 IST, virtual group meeting organized by Bank of America.
Participants
Company management to participate; specific roles not disclosed.
Purpose
Investor interaction with analysts and institutional investors.
26 Aug 2026 1 filing
No brief for this announcement. This type of announcement aren’t summarised. View the original using the link below